I am trained as a biochemist and I have worked in different fields but with a common final aim, fighting cancer. My research is focused on the identification of targets for the ubiquitin E3 ligase BRCA1/BARD1 , since deficiencies in ubiquitin E3 ligase activity of BRCA1/BARD1 are linked to cancer. BRCA1/BARD1-deficient cancer cells die specifically when we use DNA damage-inducing chemotherapeutic treatments (platinum-based compounds, PARP inhibitors, etc). However, cancer cells are able to rapidly develop resistance to these treatments.). Currently, I am working on the identification of BRCA1/BARD1 ubiquitination targets and studying their role in the DDR and cancer progression. Using a novel technique, termed Targets for Ubiquitin Ligases Identified by Proteomics (TULIP), that enables identification of BRCA1/BARD1 heterodimer-specific ubiquitination targets, we are able to uncover new players in the context of DNA damage response.
I concluded my Bachelor in Biochemistry at University of Castilla La-Mancha (Spain) performing my bachelor thesis at Bristol University (UK), in the infection and immunology department, understanding the role of both actin regulators and Programmed Death Ligand 1 (PDL1) at the immune synapse of CD4 and CD8 T cells. I then moved to the Autonomous University of Madrid (Spain) where I completed my master’s in biotechnology carrying out my final master’s dissertation at the Spanish National Biotechnology Centre (CNB-CSIC). I was working on the design of a novel protein tool box out of viral fibers, concerning protein origami. Later, I got a 1 year contract from the University of Seville (European Social Fund contract) and I was working in Andres Aguileras’s Lab at the Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER). The project was based on Genetic Instability and the identification of anti-tumoral drugs with TOP1 and TDP1 as a target. In June 2018, I joined Dr. Román González Prieto as PhD student.